The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a significant substantial loss in body mass and benefit metabolic function, particul